drugset / Trial / NCT03609905

Adipose Mesenchymal Stem Cells (AMSC) for Treatment of Ulcerative Colitis

NCT03609905 ↗

Phase 1/2 Unknown 50 enrolled Liaocheng People's Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

Ulcerative colitis is a form of inflammatory bowel disease characterized by diffuse inflammation of the colonic mucosa. It affects the rectum and extends proximally along a variable length of the colon. Ulcerative colitis is a chronic condition with a relapsing remitting course. Mesenchymal stem cells (MSCs) are a subset of adult stem cells residing in many tissues, including bone marrow (BM), adipose tissue, umbilical cord blood. Recent experimental findings have shown the ability of MSCs to home to damaged tissues and to produce paracrine factors with anti-inflammatory properties, potentially resulting in reduction of inflammation and functional recovery of the damaged tissues. The purpose of our study is to evaluate safety and efficacy of the intracolonic injection by using a colonoscope of allogeneic adipose MSCs in patients with moderate active ulcerative colitis.

Timeline

Start
2018-07-01
Primary completion
2021-06-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Adipose-cord mesenchymal stromal cells Unknown 5e+07 cells Other

Indications